These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 21727251)

  • 1. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.
    Wonodi I; Stine OC; Sathyasaikumar KV; Roberts RC; Mitchell BD; Hong LE; Kajii Y; Thaker GK; Schwarcz R
    Arch Gen Psychiatry; 2011 Jul; 68(7):665-74. PubMed ID: 21727251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls.
    Holtze M; Saetre P; Engberg G; Schwieler L; Werge T; Andreassen OA; Hall H; Terenius L; Agartz I; Jönsson EG; Schalling M; Erhardt S
    J Psychiatry Neurosci; 2012 Jan; 37(1):53-7. PubMed ID: 21693093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia.
    Wonodi I; McMahon RP; Krishna N; Mitchell BD; Liu J; Glassman M; Hong LE; Gold JM
    Schizophr Res; 2014 Dec; 160(1-3):80-7. PubMed ID: 25464917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
    Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
    J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population.
    Aoyama N; Takahashi N; Saito S; Maeno N; Ishihara R; Ji X; Miura H; Ikeda M; Suzuki T; Kitajima T; Yamanouchi Y; Kinoshita Y; Yoshida K; Iwata N; Inada T; Ozaki N
    Genes Brain Behav; 2006 Jun; 5(4):364-8. PubMed ID: 16716206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders.
    Erhardt S; Pocivavsek A; Repici M; Liu XC; Imbeault S; Maddison DC; Thomas MAR; Smalley JL; Larsson MK; Muchowski PJ; Giorgini F; Schwarcz R
    Biol Psychiatry; 2017 Nov; 82(10):756-765. PubMed ID: 28187857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.
    Tufvesson-Alm M; Schwieler L; Schwarcz R; Goiny M; Erhardt S; Engberg G
    Neuropharmacology; 2018 Aug; 138():130-139. PubMed ID: 29879409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression.
    Lavebratt C; Olsson S; Backlund L; Frisén L; Sellgren C; Priebe L; Nikamo P; Träskman-Bendz L; Cichon S; Vawter MP; Osby U; Engberg G; Landén M; Erhardt S; Schalling M
    Mol Psychiatry; 2014 Mar; 19(3):334-41. PubMed ID: 23459468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.
    Sathyasaikumar KV; Stachowski EK; Wonodi I; Roberts RC; Rassoulpour A; McMahon RP; Schwarcz R
    Schizophr Bull; 2011 Nov; 37(6):1147-56. PubMed ID: 21036897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Association of kynurenine-3-monooxygenase gene with schizophrenia].
    Golimbet VE; Lezheiko TV; Alfimova MV; Abramova LI; Kondrat'ev NV
    Genetika; 2014 Jun; 50(6):724-8. PubMed ID: 25715464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain.
    Giorgini F; Huang SY; Sathyasaikumar KV; Notarangelo FM; Thomas MA; Tararina M; Wu HQ; Schwarcz R; Muchowski PJ
    J Biol Chem; 2013 Dec; 288(51):36554-66. PubMed ID: 24189070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiency of kynurenine 3-monooxygenase exacerbates impairment of prepulse inhibition induced by phencyclidine.
    Kubota H; Kunisawa K; Niijima M; Hirakawa M; Mori Y; Hasegawa M; Fujigaki S; Fujigaki H; Yamamoto Y; Saito K; Nabeshima T; Mouri A
    Biochem Biophys Res Commun; 2022 Nov; 629():142-151. PubMed ID: 36116377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kynurenine 3-monooxygenase deficiency induces depression-like behavior via enhanced antagonism of α7 nicotinic acetylcholine receptors by kynurenic acid.
    Mori Y; Mouri A; Kunisawa K; Hirakawa M; Kubota H; Kosuge A; Niijima M; Hasegawa M; Kurahashi H; Murakami R; Hoshi M; Nakano T; Fujigaki S; Fujigaki H; Yamamoto Y; Nabeshima T; Saito K
    Behav Brain Res; 2021 May; 405():113191. PubMed ID: 33607168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kynurenine Monooxygenase Expression and Activity in Human Astrocytomas.
    Vázquez Cervantes GI; Pineda B; Ramírez Ortega D; Salazar A; González Esquivel DF; Rembao D; Zavala Vega S; Gómez-Manzo S; Pérez de la Cruz G; Pérez de la Cruz V
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variants of the kynurenine-3-monooxygenase and postpartum depressive symptoms after cesarean section in Chinese women.
    Wang SY; Duan KM; Tan XF; Yin JY; Mao XY; Zheng W; Wang CY; Yang M; Peng C; Zhou HH; Liu ZQ
    J Affect Disord; 2017 Jun; 215():94-101. PubMed ID: 28319697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of neuronal kynurenine 3-monooxygenase mediates depression-like behavior in a mouse model of neuropathic pain.
    Laumet G; Zhou W; Dantzer R; Edralin JD; Huo X; Budac DP; O'Connor JC; Lee AW; Heijnen CJ; Kavelaars A
    Brain Behav Immun; 2017 Nov; 66():94-102. PubMed ID: 28709913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Study Between Kynurenine 3-Monooxygenase (KMO) Gene and Parkinson's Disease Patients.
    Babu HWS; Elangovan A; Iyer M; Kirola L; Muthusamy S; Jeeth P; Muthukumar S; Vanlalpeka H; Gopalakrishnan AV; Kadhirvel S; Kumar NS; Vellingiri B
    Mol Neurobiol; 2024 Jul; 61(7):3867-3881. PubMed ID: 38040995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kynurenine-3-monooxygenase (KMO): From its biological functions to therapeutic effect in diseases progression.
    Chen Y; Zhang J; Yang Y; Xiang K; Li H; Sun D; Chen L
    J Cell Physiol; 2022 Dec; 237(12):4339-4355. PubMed ID: 36088660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The kynurenine pathway in schizophrenia and bipolar disorder.
    Erhardt S; Schwieler L; Imbeault S; Engberg G
    Neuropharmacology; 2017 Jan; 112(Pt B):297-306. PubMed ID: 27245499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine.
    Forrest CM; McNair K; Pisar M; Khalil OS; Darlington LG; Stone TW
    Neuroscience; 2015 Dec; 310():91-105. PubMed ID: 26365611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.